UnknownPhase 4

Biologic Therapy in Pediatric JIA Uveitis

Egypt250 participantsStarted 2022-07-01

Plain-language summary

Juvenile Idiopathic Arthritis (JIA) remains the most common systemic disorder associated with pediatric uveitis. Studies estimate that 28-67% of patients with JIA-associated uveitis develop ocular complications, with 12% developing poor visual outcome. The only means of improving long term effects of uveitis, is early and aggressive anti-inflammatory treatment, including biologics.

Who can participate

Age range3 Months – 16 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosed JIA according to rheumatological criteria with ocular affection * Any type of arthritis (oligoarticular, polyarticular, systemic onset, ocular JIA) * ANA positive or negative * Uncontrolled uveitis or frequent relapses Exclusion Criteria: * Patients without definitive diagnosis as JIA * JIA patients on biologics without ocular affection (for systemic control) or with uveitis controlled without the use of biologics * Patients without adequate duration for follow-up (less than 3 months) or lost follow up data * Patients without available data prior to the start biologics (to compare control of the uveitis)

What they're measuring

steroids sparing effect of the drug

Timeframe: 24 months

the severity and complications of the uveitis

Timeframe: 24 months

Trial details

NCT IDNCT05540743

SponsorKasr El Aini Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-12

View on ClinicalTrials.gov More Juvenile Idiopathic Arthritis Associated Uveitis trials